Nanoscan (Human Serum Albumin)

Human serum albumin increases plasma oncotic pressure by binding water and various endogenous substances. This draws fluid from the interstitial space into the bloodstream, expanding intravascular volume, supporting blood pressure, and improving tissue perfusion in states of low albumin or fluid loss.

The dose of Nanoscan is individualized. A qualified prescriber determines the amount and rate of infusion based on the patient’s serum albumin level, fluid status, and clinical condition. No fixed regimen is provided in public information.

The safety of human serum albumin in pregnancy and lactation has not been definitively established. Use should be considered only if the potential benefit justifies any possible risk to the fetus or infant, and it must be decided by the treating physician.

To order Nanoscan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with synthetic colloids or crystalloids, human serum albumin provides oncotic pressure similar to natural plasma proteins, resulting in more efficient intravascular volume expansion with less interstitial edema. However, it is more costly and requires careful monitoring for rare allergic reactions.

Nanoscan should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for administration.

Nanoscan is administered by intravenous or subcutaneous injection. The solution is typically infused slowly through a calibrated infusion set, with the rate adjusted according to the patient’s hemodynamic response and clinical guidelines provided by the prescriber.

Serious risks include anaphylactic reactions, pulmonary edema, severe hypotension or circulatory collapse, thromboembolic events, hemolysis, and acute renal failure. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Nanoscan is contraindicated in patients with known hypersensitivity to human serum albumin or any component of the formulation. Caution is advised in individuals with severe heart failure, uncontrolled hypertension, or active pulmonary edema, where volume expansion could worsen the condition.